AIM： To evaluate the effect of antiviral agents on intrahepatic HBV DNA in HBeAg-positive chronic hepatitis B patients. METHODS： Seventy-one patients received treatment with lamivudine, interferon alpha （IFN-α2b）...AIM： To evaluate the effect of antiviral agents on intrahepatic HBV DNA in HBeAg-positive chronic hepatitis B patients. METHODS： Seventy-one patients received treatment with lamivudine, interferon alpha （IFN-α2b） or sequential therapy with lamivudine-IFN-α2b for 48 wk. All subjects were followed up for 24 wk. Serum and intrahepatic HBV DNA were measured quantitatively by PCR. HBV genotypes were analyzed by PCR-RFLP. RESULTS： At the end of treatment, the intrahepatic HBV DNA level in 71 patients decreased from a mean of （6.1 ± 1.0） Iog10 to （4.9± 1.4） Iog10. Further, a larger decrease was seen in the intrahepatic HBV DNA level in patients with HBeAg seroconversion. Intrahepatic HBV DNA level （before and after treatment） was not significantly affected by the patients＇ HBV genotype, or by the probability of virological flare after treatment. CONCLUSION： Intrahepatic HBV DNA can be effectively lowered by antiviral agents and is a significant marker for monitoring antivirus treatment. Low intrahepatic HBV DNA level may achieve better efficacy of antivirus treatment.展开更多
乙型肝炎病毒(hepatitis B virus,HBV)相关性肝衰竭(liver failure,LF)是临床常见的严重肝病症候群,其治疗难度大、病死率高、预后差.核苷(酸)类似物(nucleos/tide analogues,NAs)抗病毒在慢性乙型肝炎中的显著疗效,使其在HBV相关性LF...乙型肝炎病毒(hepatitis B virus,HBV)相关性肝衰竭(liver failure,LF)是临床常见的严重肝病症候群,其治疗难度大、病死率高、预后差.核苷(酸)类似物(nucleos/tide analogues,NAs)抗病毒在慢性乙型肝炎中的显著疗效,使其在HBV相关性LF患者中的应用价值越来越受到重视.2000年以来,有学者将NAs用于LF的治疗,通过抗病毒,可有效抑制HBVDNA的复制,改善LF患者的肝功能,延长生存期,延缓或减少肝移植的需求.因此NAs抗病毒治疗对于HBV相关性LF可能具有重要的临床意义.本文重点对NAs在HBV相关性LF患者中抗病毒治疗的研究进行综述.展开更多
Hepatitis B virus(HBV) infection is one of the most serious and prevalent viral diseases in the world. Although several anti-HBV drugs have been used clinically, their side and adverse effects limit treatment efficacy...Hepatitis B virus(HBV) infection is one of the most serious and prevalent viral diseases in the world. Although several anti-HBV drugs have been used clinically, their side and adverse effects limit treatment efficacy. Therefore, it is necessary to identify novel potential anti-HBV agents. The flavonol quercetin has shown activity against some retroviruses, but its effect on HBV remains unclear. In the present study, quercetin was incubated with Hep G2.2.15 cells, as well as Hu H-7 cells transfected with an HBV plasmid. Quercetin was shown to significantly reduce Hepatitis B surface antigen(HBs Ag) and Hepatitis B e antigen(HBe Ag), secretion and HBV genomic DNA levels in both cell lines. In addition, co-incubation with lamivudine(3TC), entecavir(ETV), or adefovir(Ade) further enhanced the quercetin-induced inhibition of HBV replication. This inhibition was partially associated with decreased heat shock proteins and HBV transcription levels. The results indicate that quercetin inhibited HBV antigen secretion and genome replication in human hepatoma cell lines, which suggests that quercetin may be a potentially effective anti-HBV agent.展开更多
基金Supported by Beijing Municipal Science & Technology Commission, No. H020920020690
文摘AIM： To evaluate the effect of antiviral agents on intrahepatic HBV DNA in HBeAg-positive chronic hepatitis B patients. METHODS： Seventy-one patients received treatment with lamivudine, interferon alpha （IFN-α2b） or sequential therapy with lamivudine-IFN-α2b for 48 wk. All subjects were followed up for 24 wk. Serum and intrahepatic HBV DNA were measured quantitatively by PCR. HBV genotypes were analyzed by PCR-RFLP. RESULTS： At the end of treatment, the intrahepatic HBV DNA level in 71 patients decreased from a mean of （6.1 ± 1.0） Iog10 to （4.9± 1.4） Iog10. Further, a larger decrease was seen in the intrahepatic HBV DNA level in patients with HBeAg seroconversion. Intrahepatic HBV DNA level （before and after treatment） was not significantly affected by the patients＇ HBV genotype, or by the probability of virological flare after treatment. CONCLUSION： Intrahepatic HBV DNA can be effectively lowered by antiviral agents and is a significant marker for monitoring antivirus treatment. Low intrahepatic HBV DNA level may achieve better efficacy of antivirus treatment.
文摘乙型肝炎病毒(hepatitis B virus,HBV)相关性肝衰竭(liver failure,LF)是临床常见的严重肝病症候群,其治疗难度大、病死率高、预后差.核苷(酸)类似物(nucleos/tide analogues,NAs)抗病毒在慢性乙型肝炎中的显著疗效,使其在HBV相关性LF患者中的应用价值越来越受到重视.2000年以来,有学者将NAs用于LF的治疗,通过抗病毒,可有效抑制HBVDNA的复制,改善LF患者的肝功能,延长生存期,延缓或减少肝移植的需求.因此NAs抗病毒治疗对于HBV相关性LF可能具有重要的临床意义.本文重点对NAs在HBV相关性LF患者中抗病毒治疗的研究进行综述.
基金supported by grants from the National Major Science and Technology Special Projects for Infectious Diseases of China (2012ZX10004503-008, 2012ZX10001006-002, and 2012ZX10002006-002)National Natural Science Foundation of China (31300748)
文摘Hepatitis B virus(HBV) infection is one of the most serious and prevalent viral diseases in the world. Although several anti-HBV drugs have been used clinically, their side and adverse effects limit treatment efficacy. Therefore, it is necessary to identify novel potential anti-HBV agents. The flavonol quercetin has shown activity against some retroviruses, but its effect on HBV remains unclear. In the present study, quercetin was incubated with Hep G2.2.15 cells, as well as Hu H-7 cells transfected with an HBV plasmid. Quercetin was shown to significantly reduce Hepatitis B surface antigen(HBs Ag) and Hepatitis B e antigen(HBe Ag), secretion and HBV genomic DNA levels in both cell lines. In addition, co-incubation with lamivudine(3TC), entecavir(ETV), or adefovir(Ade) further enhanced the quercetin-induced inhibition of HBV replication. This inhibition was partially associated with decreased heat shock proteins and HBV transcription levels. The results indicate that quercetin inhibited HBV antigen secretion and genome replication in human hepatoma cell lines, which suggests that quercetin may be a potentially effective anti-HBV agent.
